API+ preparation "integration strategy. This strategy is the key layout of the strategic development of Beilu Pharmaceutical in recent years, and the capacity building of comparing APIs is one of the key tasks of the company. As a professional contrast agent supplier, during the reporting period, the Iohexol, Iohexol, Gd-DTPA and Iopamol injections of Hokuriku Pharmaceutical all passed the consistency evaluation. Among them, Iohexol injection won the bid in the fifth batch of national centralized drug procurement, and has been supplied to Beijing, Shanghai, Chongqing and other provinces, municipalities and autonomous regions since the fourth quarter of last year. In 20021year, the company's sales revenue of contrast agent products reached 635 million yuan, which was basically the same as that of the previous year. The company is developing a new product gadolinium butoxide injection, which is expected to be listed in 2022, further enriching the company's comparative product pipeline.